PCRC_S1400

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (S1400).
Inclusion Criteria:
• Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the lung confirmed by tumor biopsy and/or fine-needle aspiration; disease must be stage IV SCCA, or recurrent
• Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on current treatment
• Patients must have adequate tumor tissue available

Phase II/III
NCT02154490
Cancer
Lung
Gary Goodman, M.D.
SWOG (Southwest Oncology Group)
Brenda Fisher

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.